Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...

Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a ...

In a challenging market environment, Collegium Pharmaceutical Inc. (NASDAQ:COLL) stock has touched a 52-week low, dipping to $28.46. Despite the recent decline, InvestingPro analysis reveals ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Collegium Pharmaceutical Inc (NASDAQ:COLL) decreased during the last reporting period, falling from 6.29M to 6.11M. This put 23.48% of the company's publicly available shares short.

This page features the latest news about the Collegium Pharmaceutical stock. Collegium stock hits 52-week low at $28.46 amid market challenges In a challenging market environment, Collegium ...

GET MORE AI-GENERATED SIGNALS: January 03, 2025, 16:08 pm ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...